



BMT CTN 0201

Unrelated PB vs BM Transplants


Objective

- Compare 2 year survival probabilities between the 2 study arms using an intent-to-treat analysis

Eligibility

- AML, ALL, CML, MDS, or other myeloproliferative disorders
- 5/6 or 6/6 HLA matched unrelated donor
- Patient age < 66 years
- Donors must be ≥ 18 years, meet NMDP eligibility criteria

TREATMENT SCHEMA



To view the entire protocol, go to <http://www.bmtctn.net>
or the PDQ website at <http://cancer.gov/clinicaltrials/BMTCTN-0201>

This is a Phase III multi-center trial jointly sponsored by the NHLBI and NCI.